Sector: Health Care
Director information for LANTHEUS HOLDINGS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Brian A. Markison | Former Chief Executive Officer | [] | [] | 2026 | |
| Dr. Gérard Ber | Member; Director | 68 | ["commercial and operational management background", "extensive experience with radiopharmaceutical products", "Co-Founder and former Chief Operating Officer of Advanced Accelerator Applications S.A.", "Director, Evergreen Theragnostics, Inc.", "Director, Progenics Pharmaceuticals, Inc.", "Doctorate, Universit\u00e9 of Pharmacy of Grenoble France"] | ["Member", "Science and Technology Committee", "Talent and Compensation Committee"] | 2026 |
| Dr. James H. Thrall | Member; Chair; Director | 82 | ["Extensive experience in nuclear medicine and radiology", "Development and use of innovative new technologies, including artificial intelligence", "Distinguished Juan M. Taveras Professorship of Radiology, Harvard Medical School", "Former Chairperson of the Department of Radiology, Massachusetts General Hospital", "Former Chairperson of Radiology and Physician Trustee and Vice Chairperson of the Board of Governors of the Henry Ford Medical Staff, Henry Ford Hospital", "Former Professor, University of Michigan", "Member, National Academy of Medicine", "M.D. University of Michigan"] | ["Member", "Chair", "Nominating and Corporate Governance Committee", "Science and Technology Committee"] | 2026 |
| Dr. Ludger Dinkelborg | Head of Research and Development | 63 | [] | [] | 2026 |
| Dr. Phuong Khanh (P.K.) Morrow | Member; Director | 52 | ["Current Head of Oncology Therapeutic Area Unit (OTAU) at Takeda", "Former Chief Medical Officer, CRISPR Therapeutics", "Former Vice President and Global Therapeutic Area Head of Hematology, GI Oncology, GU Oncology, and Bone Diseases, Amgen", "Former Assistant Professor in the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center", "Hematology/Oncology fellowship at the University of Texas MD Anderson Cancer Center", "Clifton D. Howe (Fellow of the Year) Award", "American Society of Clinical Oncology Young Investigator Award", "Lyndon Baines Johnson Chief Fellow", "Internal medicine residency at Baylor College of Medicine", "M.D., University of Texas Medical School at Houston"] | ["Member", "Science and Technology Committee", "Science andTechnologyCommittee", "Talent andCompensationCommittee"] | 2026 |
| Eastland Leno | ["Corporate Finance and Capital Markets", "Accounting and Financial Reporting", "Manufacturing, Procurement and Supply Chain Management", "Risk Assessment and Management"] | [] | 2026 | ||
| Gary J. Pruden | Member; Director | 64 | ["strong financial, operational management, international and regulatory background", "extensive experience in the global pharmaceutical industry", "Former Executive Vice President, Worldwide Chairperson, Medical Devices, Johnson & Johnson", "Former Worldwide Chairperson in the Medical Devices Division, Johnson & Johnson", "Former Worldwide Chairperson of Global Surgery Group, Johnson & Johnson", "Former Company Group Chairperson, Ethicon, Inc.", "Former Worldwide President of Ethicon, Inc.", "Former President, Janssen-Ortho Inc.", "Director and Member of Compensation Committee, Ossio Inc.", "Director and Member of Compensation Committee, Avisi Technologies Inc.", "Director and Member of the Nominating and Governance Committee and Chairman of the Science and Technology Committee, Olympus Corporation", "Board of Trustees, Rider University (2011 to 2015)", "B.S. in Finance, Rider University"] | ["Member", "Chair", "Audit Committee", "Talent and Compensation Committee (Chair)"] | 2026 |
| Heino Baylor-Henry | ["Corporate Governance and ESG", "Intellectual Property", "Technology, Cybersecurity and Data Privacy", "International Experience"] | [] | 2026 | ||
| Heinz Mäusli | Member; Director | 63 | ["Audit Committee Financial Expert", "financial sophistication", "Financial and legal background", "Extensive experience with radiopharmaceutical products", "Former Chief Financial Officer at Advanced Accelerator Applications S.A. (2003 to 2018)", "Former management consultant for Accenture and Gemini Consulting", "Director, Inventiva SA", "Director and Chairperson of the Audit Committee, Progenics Pharmaceuticals, Inc."] | ["Member", "Audit Committee", "Nominating and Corporate Governance Committee"] | 2026 |
| Julie Eastland | Member; Director | 61 | ["Audit Committee Financial Expert", "financial sophistication", "Extensive biotechnology expertise across finance, strategic planning, operations and transactions", "Current President and CEO, Zentalis Corporation", "Former CEO, Harpoon Therapeutics (November 2021 until March 2024)", "Former Chief Financial and Business Officer, Rainier Therapeutics, Inc. (2018 to 2020)", "Former Chief Business Officer and Chief Financial Officer, Cascadian Therapeutics, Inc. (September 2010 until March 2018)", "Former CFO and Vice President of Finance, VLST Corporation (January 2006 until September 2010)", "Former Vice President of Strategic Planning, Dendreon Corporation (October 2000 until October 2005)", "Former Controller, Amgen (March 1996 to April 1998)", "Current Director, Zentalis Corporation", "Current Director, Member of Audit and Compensation Committees, Seismic Therapeutic (since September 2024)", "Prior Director and Chair of Audit Committee, Dynavax Technologies Corporation (July 2020 until May 2025)", "Prior Director (October 2018 until March 2024) and Chair of Audit Committee (from 2018 until 2021), Harpoon Therapeutics", "Prior Director, Graybug Vision (September 2020 until March 2023)", "B.S., Finance, Colorado State University", "MBA, Heriot-Watt University of the Edinburgh University in Scotland"] | ["Member", "Audit Committee", "Talent and Compensation Committee"] | 2026 |
| Julie McHugh | LeadIndependentDirector; Chair | 61 | ["Strong commercial and operational management background", "Extensive experience in the pharmaceutical industry", "Former Chief Operating Officer, Endo Health Solutions, Inc.", "Former CEO, Nora Therapeutics, Inc.", "Former Company Group Chairperson for the Worldwide Virology business unit of Johnson & Johnson", "Former President, Centocor, Inc.", "Led marketing communications for gastrointestinal drug Prilosec\u00ae at Astra-Merck Inc."] | ["Chair", "Nominating and Corporate Governance Committee"] | 2026 |
| Leno McHugh | ["Corporate Governance and ESG", "Intellectual Property", "Technology, Cybersecurity and Data Privacy", "International Experience"] | [] | 2026 | ||
| Mary Anne Heino | Director; Executive Chairperson and Chief Executive Officer | 66 | ["Current Executive Chairperson (since November 2025)", "CEO of the Company (since January 2026)", "Former CEO of the Company (August 2015 until March 2024)", "Former Chief Operating Officer of the Company (March 2015 until August 2015)", "Former Chief Commercial Officer of the Company (April 2013 until March 2015)", "B.S., Nursing, City University of New York", "B.S. Biology, State University of New York at Stony Brook", "MBA, Stern School of Business at New York University"] | ["Member", "Science and Technology Committee"] | 2026 |
| Minnie Baylor-Henry | Member; Director | 78 | ["regulatory and legal background", "extensive experience in the pharmaceutical industry", "Current President, B-Henry & Associates", "Former Worldwide Vice President for Regulatory Affairs, Johnson & Johnson", "Former National Director for Regulatory & Capital Markets Consulting, Deloitte & Touche", "Various former roles at U.S. Food and Drug Administration", "Former President & Board Chair, Drug Information Association", "Former Director, scPharmaceuticals", "Education: Pharmacy Degree, Howard University\u2019s College of Pharmacy", "Education: J.D., Catholic University\u2019s Columbus School of Law"] | ["Member", "Nominating and Corporate Governance Committee", "Science and Technology Committee"] | 2026 |
| Samuel Leno | Member; Chair; Director | 80 | ["Audit Committee Financial Expert", "financial sophistication", "Financial expertise", "Industry background", "Former Executive Vice President and Chief Operations Officer, Boston Scientific", "Former Executive Vice President, Finance and Information Systems and CFO, Boston Scientific", "Former Executive Vice President, Finance and Corporate Services and CFO, Zimmer Holdings, Inc.", "Former CFO, Arrow Electronics, Inc.", "Former CFO, Corporate Express, Inc.", "Former CFO, Coram Healthcare", "Various former senior financial positions at Baxter International, Inc. and American Hospital Supply Corporation", "Former Lieutenant, United States Navy", "B.S., Accounting, Northern Illinois University", "MBA, Roosevelt University"] | ["Chair", "Audit Committee"] | 2026 |
